Sustainable laundry technology developer Xeros Technology (LON: XSG) is among the top AIM performers for a second week. Non-exec Klaas de Boer bought 3 million shares at 0.82p each and fellow non-exec David Armfield bought 2.6 million shares at 0.7602p each. Dowgate has increased its shareholding from 11.4% to 13.2%. The estate of William Black has cut its stake from 8.93% to 5.24%. Two weeks ago, Xeros Technology said that it is progressing with tech verification from four global washing machine manufacturers and two of those could move to substantial paid-for joint development agreements. Timing is uncertain, though. The share price recovered a further 73.3% to 1.3p – compared with 0.525p a fortnight ago.
Iron replacement treatment developer Shield Therapeutics (LON: STX) continued its share price recovery last week with a 35% gain to 4.05p, having been 2.8p two weeks ago. This follows the announcement that 2024 revenues were $32.2m as ACCRUFeR sales in the US build up. Management is optimistic that there is enough cash to get to cash flow positive by the end of 2025. Chief executive Anders Lundstrom bought 575,000 shares at 3.7p each, taking his stake to 585,000 shares.
Light Science Technologies (LON: LST) has signed an agreement with Gavita subsidiary Agrolux Nederland to distribute its horticulture lighting products. The deal initially covers the UK and Ireland. Agrolux will sell Light Science Technologies products through its distributor network. Daniel Holliday increased his stake from 10% to 11%. There will be a capital markets day on 26 February. The share price improved 29.4% to 3.3p.
Serinus Energy (LON: SENX) has won a legal case against the Romanian tax authorities over VAT refunds. The company has been awarded a VAT refund of $1.73m for 2018 and 2019, as well as interest of $750,000. This has to be paid within 45 days. The Romanian operation is loss-making, but there are gas projects that could be developed. The 2024 results are due to be published in March and there should be news concerning how the money will be invested in the business. The share price is 18.7% higher at 2.85p, having been 3.25p earlier on Friday.
FALLERS
Immunodiagnostics developer Oncimmune (LON: ONC) increased revenues by 140% to £2.7m in the 12 months to August 2024. The loss was reduced from £3.9m to £3.2m. Cash was more than £1m at the end of January 2025 with £1.5m of debt outstanding. Strategic partnerships are being explored and additional finance will be sought. The share price slumped 56% to 4p.
Canaccord Genuity reduced its stake in online building products retailer CMO Group (LON: CMO) from 5.37% to 4.31%. The share price slid 55.8% to a new low of 4.25p.
Lord Ashcroft is trying to remove another of his companies from AIM. A general meeting has been requisitioned at wine maker Gusbourne (LON: GUS), where he owns 66.8%. Talks with potential acquirers have ended and the strategic review has been terminated. This follows Lord Ashcroft’s success in getting Merit Group and Jaywing to leave AIM. The share price dived 51.3% to 18.5p.
Drug mathematical modelling company Physiomics (LON: PYC) has raised £430,000 at 0.5p/share and could raise up to £70,000 more from a WRAP retail offer. The offer closes on 17 February. This will finance the expansion of a consulting service and market the biostatistics. It will also fund exploration of a deeper relationship with DoseMe to develop models for its platform. The share price slipped 38.2% to 0.525p.